This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
SaO039RECOMBINANT HUMAN C1 ESTERASE INHIBITOR (CONESTAT ALFA) IN THE PREVENTION OF CONTRAST-INDUCED NEPHROPATHY IN HIGH-RISK PATIENTS (PROTECT): A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND SINGLE-CENTER TRIAL. (13th June 2019)
Record Type:
Journal Article
Title:
SaO039RECOMBINANT HUMAN C1 ESTERASE INHIBITOR (CONESTAT ALFA) IN THE PREVENTION OF CONTRAST-INDUCED NEPHROPATHY IN HIGH-RISK PATIENTS (PROTECT): A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND SINGLE-CENTER TRIAL. (13th June 2019)
Main Title:
SaO039RECOMBINANT HUMAN C1 ESTERASE INHIBITOR (CONESTAT ALFA) IN THE PREVENTION OF CONTRAST-INDUCED NEPHROPATHY IN HIGH-RISK PATIENTS (PROTECT): A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND SINGLE-CENTER TRIAL